Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck

Head and Neck

Volumn 19, Issue 7, 1997, Pages 611-616

  Yasuda, Toyotoshi ^a   Sakata, Yoichi ^a   Kitamura, Ken ^a   Morita, Mamoru ^a   Ishida, Takashi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carcinoma; Head and neck; Immunohistochemistry; Inhibitor; Plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; CANCER INVASION; CORRELATION FUNCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MAXILLARY SINUS NEOPLASMS; NEOPLASM STAGING; PHARYNGEAL NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TONGUE NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 0030931986     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0347(199710)19:7<611::AID-HED8>3.0.CO;2-A     Document Type: Article

References (24)

1. Henkin J, Marcote P, Yong H. The plasminogen-plasmin system. Prog Cardiovasc Dis 1991;34:135-164.
2. Wilhelm O, Hater R, Henschen A, Schmitt M, Graeff H. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990;75: 1673-1678.
3. Pedersen H, Grøndahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-123.
4. Grøndahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Danø K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111-117.
5. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 1988;52:321-328.
6. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, et al. Metastasic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991;115:191-199.
7. Petruzzelli GJ, Snyderman CH, Johnson JT. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1994;120:989-992.
8. Ljungnér H, Björlin G, Åstedt B. Immunological identification of plasminogen activators in normal and malignant tissues of the oral cavity in man. Int J Oral Surg 1984; 13:334-338.
9. Clayman G, Wang SW, Nicolson GL, et al. Regulation of urokinase-type plasminogen activator expression in squamous cell carcinoma of the oral cavity. Int J Cancer 1993; 54:73-80.
10. Mimuro J, Loskutoff DJ. Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem, 1989;264:936-939.
11. Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood 1987;69:446-453.
12. Sakata Y, Okada M, Noro A, Matsuda M. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells. J Biol Chem 1988; 263:1960-1969.
13. Wakabayashi K, Sakata Y, Aoki N. Conformation-specific monoclonal antibodies to the calcium-induced structure of protein C. J Biol Chem. 1986;261:11097-11105.
14. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 198;256:7035-7041.
15. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8(Suppl 1):189-203.
16. Leung KC, Tung Y, Ali M, Lau WN. Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay. Cancer Lett 1991;58:233-240.
17. Andreasen PA, Nielsen LS, Kristensen P, et al. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986;261:7644-7651.
18. Skriver L, Larsson LI, Kielberg V, et al. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984;99: 752-757.
19. Kristensen P, Pyke C, Lund LR, Andreasen PA, Danø K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 1990;93:559-566.
20. Koretz K, Möller P, Schwartz-Albiez R. Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumor cells. Eur J Cancer 1993;29A:1184-1189.
21. Vecchio SD, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993; 53:3198-3206.
22. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53:2513-2521.
23. Owensby DA, Morton PA, Wun TC, Schwartz AL. Binding of plasminogen activator inhibitor type-1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 1991;266:4334-4340.
24. Tomasini-Johansson BR, Sundberg C, Lindmark G, Gailit JO, Rubin K. Vitronectin in colorectal adenocarcinoma-synthesis by stromal cells in culture. Exp Cell Res 1994; 214:303-312.